Home » Stocks » CorMedix

CorMedix, Inc. (CRMD)

Stock Price: $4.35 USD 0.18 (4.32%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 135.89M
Revenue (ttm) 174,806
Net Income (ttm) -19.91M
Shares Out 31.24M
EPS (ttm) -1.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $4.35
Previous Close $4.17
Change ($) 0.18
Change (%) 4.32%
Day's Open 4.19
Day's Range 4.06 - 4.37
Day's Volume 298,671
52-Week Range 2.16 - 8.64

More Stats

Market Cap 135.89M
Enterprise Value 113.27M
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 31.24M
Float 28.92M
EPS (basic) -1.88
EPS (diluted) -1.85
FCF / Share -0.64
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.16M
Short Ratio 7.00
Short % of Float 10.30%
Beta 2.76
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 777.36
PB Ratio 6.68
Revenue 174,806
Operating Income -25.08M
Net Income -19.91M
Free Cash Flow -16.60M
Net Cash 22.62M
Net Cash / Share 0.72
Gross Margin -51.47%
Operating Margin -14,347.16%
Profit Margin -11,389.30%
FCF Margin -9,495.16%
ROA -60.53%
ROE -113.78%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$10.50*
(141.38% upside)
Low
10.0
Current: $4.35
High
11.0
Target: 10.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.280.430.330.220.210.19----
Revenue Growth-34.09%30.51%46.95%6.65%11.02%9358.97%----
Gross Profit-0.090.030.21-0.14-0.11-0.26-0.20---
Operating Income-21.01-26.86-32.92-24.76-16.65-8.90-4.92-3.00-7.21-8.51
Net Income-16.43-26.83-33.01-24.64-18.19-20.45-9.13-3.38-6.67-10.91
Shares Outstanding24.1517.8211.037.596.274.292.762.282.281.89
Earnings Per Share-1.80-1.51-3.00-3.25-2.90-4.80-3.45-1.50-2.90-5.75
Operating Cash Flow-15.05-23.70-28.59-22.27-12.53-6.32-3.62-2.28-6.30-3.67
Capital Expenditures-0.04-0.05-0.15-0.06-0.02-0.03-0.04---0.01
Free Cash Flow-15.09-23.75-28.74-22.32-12.54-6.35-3.65-2.28-6.30-3.68
Cash & Equivalents28.5117.8012.1620.3435.564.342.590.841.998.28
Total Debt-6.13-----0.27--
Net Cash / Debt28.5111.6712.1620.3435.564.342.590.571.998.28
Assets29.4818.8313.4521.9137.105.102.971.152.568.85
Liabilities5.8313.896.264.093.091.466.991.491.221.59
Book Value23.654.937.1917.8134.013.63-4.02-0.341.337.26
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CorMedix, Inc.
Country United States
Employees 30
CEO Mohammed Khoso Baluch

Stock Information

Ticker Symbol CRMD
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: CRMD
IPO Date March 25, 2010

Description

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.